IP Verse

Stable Semaglutide Compositions And Uses Thereof - EP3870213

EP3870213

NOVO NORDISK
Application Number
EP19801228A
Filing Date
Oct 25, 2019
Status
Granted And Under Opposition
May 5, 2023
Grant Date
Jun 7, 2023
External Links
Slate, Register, Google Patents

Bibliography

The patent EP3870213B1 was granted to Novo Nordisk on Jun 7, 2023 following the initial filing on Oct 25, 2019 under the application number EP19801228A . The current legal status of the patent is Granted And Under Opposition.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMar 7, 2024ADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2006097537
INTERNATIONAL-SEARCH-REPORTWO2005049061
INTERNATIONAL-SEARCH-REPORTWO2016038521
INTERNATIONAL-SEARCH-REPORTWO2017186896
INTERNATIONAL-SEARCH-REPORTWO2018115901
OPPOSITIONEP1197222
OPPOSITIONWO0149314
OPPOSITIONWO03002136
OPPOSITIONWO2006097537
OPPOSITIONWO2012080471
OPPOSITIONWO2013127779
OPPOSITIONWO2013139694
OPPOSITIONWO2020084126
OPPOSITIONWO9924071

Non-Patent Literature (NPL) Citations (5) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- LEVINE, Methods. Enzymol., (19990000), vol. 309, pages 274 - 284-
DESCRIPTION- NAIKI et al., Anal. Biochem., (19890000), vol. 177, pages 244 - 249-
DESCRIPTION- WHO, Drug Information, (20100000), vol. 24, no. 1-
OPPOSITION- Anonymous, "OZEMPIC (semaglutide) injection, for subcutaneous use", OZEMPIC HIGHLIGHTS OF PRESCRIBING INFORMATION, FDA - Food and Drug Adminstration, (20171201), pages 1 - 44, OZEMPIC HIGHLIGHTS OF PRESCRIBING INFORMATION, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf, XP093171358-
OPPOSITION- Novo Nordisk Inc., "Approval Package for: Ozempic injection", Approval Package for: Ozempic injection, FDA - CENTER FOR DRUG EVALUATION AND RESEARCH, (20171205), pages 1 - 11, Approval Package for: Ozempic injection, URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209637Orig1s000Approv.pdf, XP093171445-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents